Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 401-409

  Saison, J ^a,b,d,e   Ferry, T ^b,d,e   Demaret, J ^a   Maucort Boulch, D ^c,d,f   Venet, F ^a,d   Perpoint, T ^b   Ader, F ^b,d,e   Icard, V ^b,e   Chidiac, C ^b,d,e   Monneret, G ^a,d   Peyramond, D ^g   Cotte, L ^g   Miailhes, P ^g   Biron, F ^g   Boibieux, A ^g   Braun, E ^g   Champagne, H ^g   Daoud, F ^g   Gueripel, V ^g   Koffi, J ^g   Longuet, C ^g   Pailhes, S ^g   Ponceau, B ^g   Schlienger, I ^g   Senechal, A ^g   Bouaziz, A ^g   Karsenty, J ^g   Andre P ^g   Trabaud, M A ^g   Tardy, J C ^g   Scholtes, C ^g   Poitevin, F ^g   Malcus, C ^g   more..

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^f Equipe Biostatistique Santé   (France)

^g NONE

Author keywords

HAART; Immune activation; Immunological response; Regulatory T cells; Very low level viraemia

Indexed keywords

MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIREMIA;

HAART; IMMUNE ACTIVATION; IMMUNOLOGICAL RESPONSE; REGULATORY T CELLS; VERY LOW-LEVEL VIRAEMIA;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84899101494     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12278     Document Type: Article

References (61)

1. Grabar S, Le Moing V, Goujard C etal. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
2. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-1335.
3. Gilson RJ, Man SL, Copas A etal. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2010; 11:152-160.
4. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012; 2012:670957.
5. Li T, Wu N, Dai Y etal. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis 2005; 53:944-951.
6. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
7. Rodger AJ, Lodwick R, Schechter M etal. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
8. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992; 90:376-382.
9. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139-147.
10. Marziali M, De Santis W, Carello R etal. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006; 20:2033-2041.
11. Erikstrup C, Kronborg G, Lohse N, Ostrowski SR, Gerstoft J, Ullum H. T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication. J Acquir Immune Defic Syndr 2010; 53:303-310.
12. Delobel P, Nugeyre MT, Cazabat M etal. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006; 80:10229-10236.
13. Nakanjako D, Ssewanyana I, Mayanja-Kizza H etal. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011; 11:43.
14. Mendez-Lagares G, del Pozo Balado Mdel M, Genebat Gonzalez M, Perganeda Sanchez AG, Leal Noval M, Pacheco Lopez YM. Severe immune dysregulation affects CD4(+)CD25(hi)FoxP3(+) regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J Infect Dis 2012; 205:1501-1509.
15. Mendez-Lagares G, Garcia-Perganeda A, Pozo-Balado M etal. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. J Antimicrob Chemother 2012; 67:1228-1237.
16. Doyle T, Smith C, Vitiello P etal. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:724-732.
17. Maggiolo F, Callegaro A, Cologni G etal. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012; 60:473-482.
18. Gianotti N, Galli L, Racca S etal. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 2012; 67:213-217.
19. Bastard JP, Soulie C, Fellahi S etal. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther 2012; 17:915-919.
20. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62:87-92.
21. Charpentier C, Landman R, Laouenan C etal. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother 2012; 67:2231-2235.
22. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005; 191:348-357.
23. Fazekas de St Groth B, Landay AL. Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 2008; 22:671-683.
24. Kassiotis G, O'Garra A. Immunology. Immunity benefits from a little suppression. Science 2008; 320:1168-1169.
25. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 320:1220-1224.
26. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol 2012; 86:10262-10269.
27. Horta A, Nobrega C, Amorim-Machado P etal. Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells. PLOS ONE 2013; 8:e57336.
28. Foxall RB, Albuquerque AS, Soares RS etal. Memory and naive-like regulatory CD4+ T cells expand during HIV-2 infection in direct association with CD4+ T-cell depletion irrespectively of viremia. AIDS 2011; 25:1961-1970.
29. Nilsson J, Boasso A, Velilla PA etal. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006; 108:3808-3817.
30. Tenorio AR, Martinson J, Pollard D, Baum L, Landay A. The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr 2008; 48:577-580.
31. Lim A, Tan D, Price P etal. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21:1525-1534.
32. Del Pozo-Balado Mdel M, Leal M, Mendez-Lagares G, Pacheco YM. CD4(+)CD25(+/hi)CD127(lo) phenotype does not accurately identify regulatory T cells in all populations of HIV-infected persons. J Infect Dis 2010; 201:331-335.
33. Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr 2010; 54:447-454.
34. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008; 82:8307-8315.
35. Jiao Y, Fu J, Xing S etal. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology 2009; 128:e366-375.
36. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
37. Saison J, Tardy JC, Scholtes C etal. Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction. J Med Virol 2013; 85:953-958.
38. Demaret J, Saison J, Venet F etal. Assessment of a novel flow cytometry technique of one-step intracellular staining: example of FOXP3 in clinical samples. Cytometry B Clin Cytom 2013; 84:187-193.
39. Piconi S, Trabattoni D, Gori A etal. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS 2010; 24:1991-2000.
40. Andrade RM, Hygino J, Kasahara TM etal. High IL-10 production by aged AIDS patients is related to high frequency of Tr-1 phenotype and low in vitro viral replication. Clin Immunol 2012; 145:31-43.
41. Casotti JA, Passos LN, Oliveira FJ, Cerutti C, Jr. Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study. BMC Infect Dis 2011; 11:306.
42. Arguello RJ, Balbaryski J, Barboni G, Candi M, Gaddi E, Laucella S. Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients. Clin Exp Immunol 2012; 168:224-233.
43. Negredo E, Massanella M, Puig J etal. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010; 50:1300-1308.
44. Le T, Wright EJ, Smith DM etal. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218-230.
45. Gaardbo JC, Nielsen SD, Vedel SJ etal. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy. Clin Exp Immunol 2008; 154:80-86.
46. Kared H, Lelievre JD, Donkova-Petrini V etal. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008; 22:2451-2460.
47. Saison J, Demaret J, Venet F etal. CD4+CD25+CD127- assessment as a surrogate phenotype for FOXP3+ regulatory T cells in HIV-1 infected viremic and aviremic subjects. Cytometry B Clin Cytom 2012; 84:50-54.
48. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
49. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6:353-360.
50. Simonetta F, Lecuroux C, Girault I etal. Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection. J Infect Dis 2012; 205:1510-1519.
51. Hodi FS, Butler M, Oble DA etal. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-3010.
52. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7:880-887.
53. Girard PM, Katlama C, Pialoux G. VIH. DOIN Editors. Rueil-Malmaison, France: Wolters Kluwer France, 2011.
54. Li T, Wu N, Dai Y etal. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis 2011; 53:944-951.
55. Benito JM, Lopez M, Lozano S etal. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:373-381.
56. Tiba F, Nauwelaers F, Traore S etal. Immune reconstitution during the first year of antiretroviral therapy of HIV-1-infected adults in rural Burkina Faso. Open AIDS J 2012; 6:16-25.
57. Freguja R, Gianesin K, Mosconi I etal. Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children. Clin Exp Immunol 2011; 164:373-380.
58. Shaw JM, Hunt PW, Critchfield JW etal. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol 2011; 85:11422-11434.
59. Hunt PW, Landay AL, Sinclair E etal. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLOS ONE 2011; 6:e15924.
60. Prendergast A, O'Callaghan M, Menson E etal. Factors influencing T cell activation and programmed death 1 expression in HIV-infected children. AIDS Res Hum Retroviruses 2012; 28:465-468.
61. Rallon NI, Lopez M, Soriano V etal. Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. Clin Exp Immunol 2009; 155:35-43.